CG Oncology (CGON) Consolidated Net Income (2023 - 2026)

CG Oncology (CGON) has 4 years of Consolidated Net Income data on file, last reported at -$443.0 million in Q1 2026.

• Quarterly Consolidated Net Income fell 263.8% year-over-year to -$443.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$866.6 million (down 72.23% YoY) and the FY2025 annual result came in at -$359.4 million, down 83.18% from the prior year.
• Consolidated Net Income retreated to -$443.0 million in Q1 2026, from -$41.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$8.9 million in Q1 2023 to a low of -$443.0 million in Q1 2026.
• A 4-year average of -$128.2 million and a median of -$121.8 million in 2025 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2024 — Consolidated Net Income tumbled 2673.52% — and 2025, when it jumped 50.92%.
• Tracing CGON's Consolidated Net Income over 4 years: stood at -$16.6 million in 2023, then tumbled by 92.52% to -$31.9 million in 2024, then dropped by 28.6% to -$41.0 million in 2025, then plunged by 981.1% to -$443.0 million in 2026.
• The last three Consolidated Net Income figures came in at -$443.0 million (Q1 2026), -$41.0 million (Q4 2025), and -$234.4 million (Q3 2025), per Business Quant data.